National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants to offer a new grant opportunity seeking proposals to advance the understanding of the mechanisms of action, underlying biology, and clinical activity of talazoparib in prostate cancer.
LOIs are due by June 21, 2021.